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ABSTRACT
Cell cycle progression is orchestrated by E2F factors.
We previously reported that in ETS-driven cancers of
the bone and prostate, activating E2F3 cooperates
with ETS on target promoters. The mechanism of
target co-regulation remained unknown. Using RNAi
and time-resolved chromatin-immunoprecipitation in
Ewing sarcoma we report replacement of E2F3/pRB
by constitutively expressed repressive E2F4/p130
complexes on target genes upon EWS-FLI1 modula-
tion. Using mathematical modeling we interrogated
four alternative explanatory models for the observed
EWS-FLI1/E2F3 cooperation based on longitudinal
E2F target and regulating transcription factor expres-
sion analysis. Bayesian model selection revealed the
formation of a synergistic complex between EWS-
FLI1 and E2F3 as the by far most likely mecha-
nism explaining the observed kinetics of E2F target
induction. Consequently we propose that aberrant
cell cycle activation in Ewing sarcoma is due to the
de-repression of E2F targets as a consequence of
transcriptional induction and physical recruitment of
E2F3 by EWS-FLI1 replacing E2F4 on their target pro-
moters.
INTRODUCTION
Ewing sarcoma (ES) is a highly aggressive pediatric can-
cer of the bone and soft tissue characterized by a gene fu-
sion between the Ewing sarcoma gene EWSR1 (Ewing sar-
coma breakpoint region 1) and one of five alternative ETS
(E twenty-six) transcription factor genes, most frequently
FLI1 (Friend leukemia virus integration site 1). The re-
sultant oncogenic transcription factor binds DNA via the
ETS DNA-binding domain and aberrantly regulates tran-
scription of its target genes via the EWS amino terminal
domain (1,2). EWS-FLI1 activated genes associate mainly
with cell cycle regulation and proliferationwhile EWS-FLI1
repressed genes predominantly annotate to differentiation
and cell communication. Promoters of EWS-FLI1 induced
genes are strongly enriched in E2F motifs (3).
The E2F family of transcription factors consists of eight
genes, which are transcribed in nine proteins and jointly reg-
ulate cell cycle progression (4–6). Traditionally themembers
are divided into transcriptional activators (E2F1–3A, B)
and transcriptional repressors (E2F4-8) (6–9) though this
categorization may not be as strict as originally assumed
(10). E2F3b, E2F4 and E2F5 are constantly expressed
throughout the cell cycle while E2F1-3a levels increase at
cell cycle entry (9). Although E2F1–5 proteins comprise
the same pocket protein binding domain, their interaction
partners vary. E2F1–3A/B associate exclusively with pRB,
while E2F4 binds to p130 and p107, and E2F5 interacts
with p130 and pRB. E2F6–8 do not bind pocket proteins
and act as transcriptional repressors only (8,11). E2F1–6
require dimerization with members of the differentiation-
regulated transcription factor-1 polypeptide (DP) family to
form functional transcription complexes on DNA. E2F7
and 8 lack a dimerization domain, but comprise tandem re-
peats of an E2F DNA binding domain (12,13).
Recently, we demonstrated aberrant ETS-dependent in-
duction of E2F3 and concomitant, functionally synergis-
tic ETS and E2F3 binding to proximal promoters of al-
most 50% of E2F target genes in cancers driven by ETS
rearrangements, EWS-FLI1 expressing ES and TMPRSS2-
ERG positive prostate cancer (14). In fact, knockdown of
the chimeric ETS proteins by RNAi revealed that most E2F
factors expressed in these tumors are controlled by ETS
oncogenes except for E2F4, which we found constitutively
expressed at high levels. Since E2F4 is considered a tran-
scriptional repressor, we wondered if there was any kind of
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functional cross-talk between ETS induced E2F3 and E2F4
function.
MATERIALS AND METHODS
Cells and transfections
A clone of the ESFT cell line A673 with a stably transfected
construct harboring a doxycyclin inducible shRNA against
the EWS-FLI1 fusion protein was kindly provided by Javier
Alonso (15). Cells were transfected using the Lipofectamine
Plus reagent (Invitrogen, Groningen, the Netherlands).
Transcription Factor binding site analysis
Transcription factor binding site analysis was performed
using ConSite (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/
consite).
Thymidine block
Complete Dulbecco’s modified Eagle’s medium (DMEM)
medium with 2 mM Thymidine was added to the cells for
16 h, then the cells were washed twice with DMEM and
incubated in normal DMEM for 8 h, followed by a second
Thymidine block for 16 h.
Cell cycle analysis
Cell cycle analysis was performed using the CycletestTM
Plus DNA Reagent Kit (Becton Dickinson, New Jersey,
USA) according to manufacturer’s recommendations.
Chromatin immunoprecipitation and sequencing
Chromatin immunoprecipitation (ChIP) was performed us-
ing a ChIP-IT kit from Active Motif (Carlsbad, CA, USA),
following the manufacturer’s instructions with minor mod-
ifications. Briefly, A673 cells were cross-linked with 1%
formaldehyde at room temperature for 15 min. Then the
cells were sheared with a VirSonic 100 sonicator for 20 cy-
cles of 10× 1-s pulses. The chromatin was immunoprecip-
itated overnight at 4◦C. The antibody used was E2F4 (sc-
866) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
A mixture of Protein-G and Protein-A agarose beads was
applied in pull-down experiments. After reversal of cross-
linking at 65◦C overnight, the ChIP DNA was purified us-
ing spin columns provided by the kit. For sequencing, the
ChIP DNA was polymerase chain reaction (PCR) ampli-
fied and subsequently analyzed on an Illumina G1 Genome
Analyzer (San Diego, CA, USA) following manufacturer’s
protocols.
Sequence reads were mapped to the human reference
genome (NCBIv37, Hg19) using BWA (16) alignment pro-
gram. Reads starting at identical positions, as well as low
quality reads with more than two deviations from the refer-
ence or an alignment score less than 25 were removed from
the resulting data sets. Local read densities were then es-
timated by counting coverage of read-events for each nu-
cleotide in the genome, where the oriented reads were ex-
tended to the insert length (100 bp), which was size-selected
during library preparation.
P-values were used to identify significantly increased read
densities. They were estimated based on the cumulative
Poisson distribution, where the local emission coefficient
(x) was estimated from input (non-IP) data using the av-
erage read densities of windows centered around x of sizes
1 bp, 100 bp, 1000 bp, respectively. Of those, the most con-
servative (largest) estimate max i(x) was used in order to
minimize the false discovery rate. Discrete enriched regions
were identified using the following heuristic: a continuous
stretch of DNA was called significantly enriched if the fol-
lowing conditions were met simultaneously: P < 10−9 any-
where within that region, and P ≤ 10−6 everywhere else.
Subsequently, distinct significant regions were merged into
a single region if they were less than 12 fragment size (50 bp)
apart. Finally, regions determined in this way smaller than
the median fragment length (100 bp) were rejected.
Chromatin Immunoprecipitation followed by PCR
ChIP was performed using the MAGnifyTM Chromatin
Immunoprecipitation System (Invitrogen, Groningen, The
Netherlands) according to manufacturer’s instructions.
Cells were cross-linked with 1% formaldehyde at room tem-
perature for 13 min; the reaction was stopped with 125
mM Glycine for 7 min. The cells were then sheared with
a Bioruptor UCD200 5 times 7 min of alternating 30 s son-
ication and 30 s break to achieve an average shearing size
of 600 bp. Incubation times for antibody coupling and for
binding chromatin to the beads were increased to 2 h and
4 h, respectively. Washing steps were extended to 20 min
each. An additional washing step was introduced between
IP Buffer1 and 2 using 0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mMTris HCl, 500mM NaCl, pH8,1.
Following antibodies were used: anti-FLI1 antibody
(MyBiosource, San Diego, California, USA, MBS300723),
anti-E2F3 (Santa Cruz Biotechnology, Santa Cruz, USA
sc-878), anti-E2F4 (Santa Cruz Biotechnology Inc., Santa
Cruz, USA, sc-866), anti-RB (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, USA, sc-50) and anti-p130 (Santa
Cruz Biotechnology Inc., Santa Cruz, USA, sc-317), IgG
control antibodies were from the MAGnifyTM Chromatin
Immunoprecipitation System (Invitrogen, Groningen, The
Netherlands). Data were normalized to the input con-
trol according to the following equation: Normalized to
Input = 2∧(Average Ct Input – Average Ct IP). Semi-
quantitative PCRs were performed using Phusion Hotstart
II (Finnzymes, Espoo, Finland). Sybr Green PCR for ChIP
was performed usingMaximaTM SYBRGreen/ROXqPCR
Master Mix (Fermentas).
Primers used were:
ATAD2, 26/129: GAGCGCGGAAGAGCCAGAG and
GCTGCTGCGGAGAACCACCA; -350/-240: CAGG
GGTGGGGAGGAGACGC and GAGCGGTGCGTA
GCCCGTTT; -1678/-1470: CCCAGACATTGCATTC
TTCA and GAGGCCAATGAGAACAGAGC.
E2F3, 131/262: CCAGAGCCCCGATTATTTTT and GC
AGTCGGAGTTTCCAAGTC; -123/62: CGGGTTGA
GGGGCGGGGATA and TGCAACGGATTGCGAG
GCGG; -272/-149: TCAAGGAGGCCTATGCAAAT
and GGCCGCTACCTCCTTACTTC; -1457/-1334: AA
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GGAGTCCTAGCCTGATCTGA and TGAGGATTGC
AACACCTTGA.
RAD51, -51/106: ATCCGGGAGGCGGGGATACG
and CAGTTCCCAGCTGCACGCCT; -186/-51:
CCACCGCCCCCGGCATAAAG and CGTATC
CCCGCCTCCCGGAT; -93/104: CGTCTTGGGTTA
GCGCGCAG and GTTCCCAGCTGCACGCCTCG;
-4270/-4017: AGGCAGGAGTATCGCTTGAA and
CCATTTGAGGCCAGGAGTTA.
RAD54L 81/222: TTGGGAACAGGAAGGTTGAG and
TCAGACTCAGGGAGGTCGAG; MIK67, -201/329:
AGCCCTCCACTTCCTTCTTC and CGCTCCCTTC
CTATTGGTC. ATAD5, 5/154: GAAGCTCTGTGGTC
CGATCT and ACGGAAAGAGGCAATGAGAA
Plasmids
Promoter fragments (E2F3: -272/+327; RAD51: -
186/+164) were cloned into the pGL4.10 vector (Promega).
Gene reporter assays
Cells were co-transfected with the pGL4.10-based reporter
constructs and pmaxEGFP (Amaxa GmbH, Cologne, Ger-
many) using LipofectAMINE Plus reagent (Invitrogen,
Groningen, TheNetherlands) at 20%density.Gene reporter
assays for cells treated with Thymidine, were performed 48h
after transfection using the Bright Glo Luciferase assay kit
(Promega). EGFPpositive cells as ameasure of transfection
efficiencies were monitored by standard flow cytometry.
Generation of quantitative longitudinal RNA and protein ex-
pression data for mathematical modeling
Total RNA was prepared with a Qiagen RNAeasy kit (Qi-
agen, Hilden, Germany). cDNA was generated from 1g
RNA (M-MLV Reverse Transcriptase, Promega, Madison,
USA) and qRT-PCR performed using MaximaTM SYBR
Green/ROX qPCR Master Mix (Fermentas). Assays were
performed in triplicate using the ABI Prism 7900 Detection
System (Applied Biosystems, Foster City, CA, USA).
Relative expression levels were normalized to b-actin and
analyzed by the 2(-Ct) method (17)
Total proteins (30–50 g) were resolved by 8.5% SDS-
PAGE and processed for immunoblotting according to
standard procedures. The following antibodies were used:
mousemonoclonal antibody to b-actin (8226, abcam, Cam-
bridge, UK), anti-E2F3 (Santa Cruz Biotechnology, Santa
Cruz, USA sc-878) and anti-FLI1 antibody (MyBiosource,
San Diego, California, USA, MBS300723). Linear protein
quantification was performed using fluorescent dye coupled
secondary antibodies (Dy LightTM800, Pierce Biotechnol-
ogy, THP, Vienna, Austria) for detection by the LICOR
Odyssey R© Infrared Imaging System (LI-COR Biosciences,
Bad Homburg, Germany).
Co-Immunoprecipitation
For Co-Immunoprecipitation with Ab-Crosslinking Dyn-
abeads (Invitrogen, Groningen, The Netherlands) were in-
cubated with the Ab over night at 4◦C. After washing with
0,2MNa-Borate (pH 9,0), the beads were cross-linked with
the antibody using Dimethyl pimelimidate dihydrochlo-
ride. Washing with 250 mM Tris and preelution using 0,1
M Glycine (pH 2.0); was followed by incubation of the
cell lysate over night at 4◦C. After washing with IP lysis
buffer, elution was performed using 0,1MGlycine (pH 2.0).
The following antibodies were used: anti-E2F3 (Santa Cruz
Biotechnology, Santa Cruz, USA sc-878), anti-E2F4 (Santa
Cruz Biotechnology, Santa Cruz, USA sc-866), anit-RB
(Santa Cruz Biotechnology, Santa Cruz, USA sc-50), anti-
p130 (Santa Cruz Biotechnology, Santa Cruz, USA sc-317)
and anti-FLI1 antibody (MyBiosource, San Diego, Califor-
nia,USA,MBS300723). Immunoblottingwas performed as
described above.
BAYESIAN MODEL SELECTION AND STATISTICAL
METHODOLOGY
ODE formation of mechanistic models
To formulate the kinetic equations of the four models (as
described in the results section) as ordinary differential
equations (ODEs), some notation is introduced first. Let
{.}{R,D,P} be the mRNA, DNA concentration and protein
level of a gene, respectively. For instance, EWSR refers to
the mRNA concentration of EWS-FLI1 while E2F3P to
the E2F3 protein level. Complexes are named by combin-
ing the names of their components followed by the {·}C su-
perscript. For example, E2F3PATAD2CD denotes the com-
plex formed by the binding of E2F3 protein on the ATAD2
DNA. Species concentrations in ODEs are denoted as[{.}{R,D,P}
]
, e.g. [EWSR] denotes the concentration of EWS-
FLI1 mRNA.
The ODE representation of the system involving the for-
mation of a dimer (model 2, Figure 4B) is provided as a rep-
resentative example (the ODE representations of model 1,3
and 4 including the parameters of the models are available
in the supportingmaterial and Supplementary Tables S1, S2
and S3). The derivation of the ODE system assumes mass
action kinetics. The total DNA concentration of the model
consists of DNA in two forms, free and in a complex. For
example, it holds for the complexes EWSPE2F3CP,D and
E2F3D that
d[EWSPE2F3CP,D]
dt =
c1 [EWSP] [E2F3P] [E2F3D] − c−1EWSPE2F3CP,D = 0.
Furthermore, the total concentration
[
E2F3totalD
]
of
E2F3D is given by
[
E2F3totalD
] = [E2F3D] +
[
EWSPE2F3CP,D
]
,
therefore
[
EWSPE2F3CP,D
] = [EWSP] [E2F3P]
[
E2F3totalD
]
[EWSP] [E2F3P] + c−1c1
.
The ODE system of model 2 is then
d [EWSR]
dt
= −mˆ1 [EWSR] − d1 [EWSR] + a1, (1)
d [EWSP]
dt
= t1 [EWSR] − d2 [EWSP] , (2)
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d[E2F3R]
dt =
k1
[EWSP ][E2F3P ][E2F3totalD ]
[EWSP ][E2F3P ]+cˆ1 − d3 [E2F3R] ,
(3)
d [E2F3P]
dt
= t2 [E2F3R] − d4 [E2F3P] , (4)
d[ATAD2R]
dt =
k2
[EWSP ][E2F3P ][ATAD2totalD ]
[EWSP ][E2F3P ]+cˆ2 − d5 [ATAD2R] ,
(5)
where mˆ1 = m1 [shRNA], cˆ1 = c−1/c1, cˆ2 = c−2/c2. The pa-
rameters of the model and its description are provided in
Table 1.
Additionally, to avoid identification problems with
transcription parameters k1,k2 and total concen-
trations
[
E2F3totalD
]
,
[
ATAD2totalD
]
the following re-
parameterisation is introduced:
̂kˆ1 = k1
[
E2F3totalD
]
,
̂kˆ2 = k2
[
ATAD2totalD
]
.
MCMC inference
The ODEs of the mechanistic models under consideration
are modeled as
dx
dt
= f (x, t, θ ) , x (t1) = x1,
where the derivative dx/dt of state x is, for instance, the left
hand side of the ODE system (1)-(5) and f (x, t, θ ) the right
hand side. x(t) is the solution of the ODE for time t, and
x1 are the unknown initial conditions at the starting time
point t1. All unknown parameters, including initial condi-
tions, are collected in the vector θ . It is assumed that each
observation yi, at time point ti , i = 1, 2, . . . , nt, is a linear
combination of the solution vector xi, with Gaussian addi-
tive noise i. Since we are dealing with RNA and protein
expression data with different experimental and measure-
ment conditions, we use two distinct noise variances, vr and
vp, to model observation noise for RNA and protein data
respectively. Thus the observation model at time point ti is
of the form
yi, = xi, + εi , εi, ∼ N (0,V) ,
where V is a diagonal matrix formed as V = vr Ir + vp Ip.
Ir is an identity matrix with zeros in the diagonal elements
that correspond to protein level variables, and similarly, Ip
is an identity matrix with zeros in the diagonal elements
which correspond to RNA expression variables. Since vr
and vp are unknown, they are appended to the vector θ
of model parameters giving the complete parameter vector
φ = (θ, vr , vp).
Assuming that observations are obtained independently
at each time point for each measured level, we can now
use the observation model to calculate the likelihood of the
data conditional on themodel and the correspondingmodel
parameters. Denoting the jth level, j = 1, 2, . . . , ns, of the
solution of the mth, m = 1, 2, 3, 4, ODE model at time
point ti , i = 1, 2, . . . , nt, as x(m)i j
(
θ (m)
)
with the correspond-
ing model parameters θ (m), the likelihood for modelMm is
p
(
Y|φ(m), Mm
) =
nt∏
i=1
ns∏
j=1
1i j N(yi j |x(m)i j
(
θ (m)
)
, vi j ).
The experimental data described earlier correspond to
the observation matrix Y of the statistical model and are
available in the supporting material (Supplementary Figure
S4). The indicator fucntion 1i j accounts for missing data. If
level j has been measured at time point ti, then 1i j = 1. On
the other hand, if an experimental observation has not been
made at time point ti for species j, then 1i j = 0. vi jdenotes
the (i,j)th element of noise variance matrix V.
For comparing different models, e.g M1 versus M2, as-
suming that all models are a-priori equally probable we need
to calculate the Bayes factor
p(Y|M1)
p(Y|M2) =
∫ p (Y|φ(1), M1
)
p(φ(1)|M1)dφ(1)
∫ p (Y|φ(2), M2
)
p(φ(2)|M2)dφ(2)
, (6)
where p(φ(1)|M1) is the prior distribution for the parameters
of the corresponding model. The integrals in equation (6)
are the marginal likelihoods of the models which are calcu-
lated using Markov Chain Monte Carlo by sampling from
the posterior distribution of the parameters p
(
φ(m)|Y, Mm
)
.
Due to the non-linear dependence of the ODE models on
the parameters the posteriors exhibit multiple local max-
ima and strong correlations. Therefore we employ a pop-
ulationMCMC sampler for sampling from 50 power poste-
riors (18) with a simplified Manifold Metropolis-Adjusted
LangevinAlgorithm [simplifiedMMALAsee (19)]. Popula-
tionMCMC allows the algorithm to sample between differ-
ent local maxima while the simplified MMALA allows for
efficient sampling under strong correlation regimes. More
details on the implementation of the MCMC inferential
scheme can be found in the ‘Supplements’. Previous work in
systems biology as exemplified by (20) has employed similar
mechanistic models formed by systems of ODEs to study
gene regulatory networks with great success. In (20) how-
ever, the models were scored by carefully constructing func-
tions measuring how the models fit several aspects of the
data and optimizing the model parameters. In our work
we construct a Bayesian model selection framework by us-
ing Bayes factors computed by properly marginalizing all
model parameters and associated uncertainty out of the
models. The methodology presented in this paper is more
similar to the work in (21).
RESULTS
E2F4 co-localization with E2F3 and EWS-FLI1
To compare E2F3 and E2F4 binding patterns in ES, E2F4
specific ChIP-seq was performed on the same A673 ES cell
line-derived chromatin previously used in EWS-FLI1 and
E2F3 specific pull-down experiments (14). In brief, after
preprocessing 12.7 Mio. reads were uniquely aligned to the
human genome (hg19) corresponding to 1816 distinct ge-
nomic E2F4 binding regions [all alignment/peak-finding
parameters essentially as in (14)]. Of these 1816 peaks, 1151
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Table 1. Parameters and description for model 2
Parameter Description
a1 EWS-FLI1 transcription rate times EWS-FLI1 DNA concentration
m1 shRNA mediated degradation rate constant of EWS mRNA
d1 EWS-FLI1 mRNA degradation rate constant
t1 EWS-FLI1 translation rate constant
d2 EWS-FLI1 protein degradation rate constant
k1 EWS-FLI1 mediated E2F3 transcription rate constant
c1 EWS-FLI1 E2F3 association rate constant
c-1 EWS-FLI1 E2F3 disassociation rate constant
k2 Complex ATAD2 transcription rate constant
c2 E2F3 protein E2F3 DNA association rate constant
c-2 E2F3 protein E2F3 DNA disassociation rate constant
d3 E2F3 mRNA degradation rate constant
t2 E2F3 translation rate constant
d4 E2F3 protein degradation rate constant
d5 ATAD2 mRNA degradation rate constant
and 1159 (63.4% and 63.8%) overlapped with E2F3 and
EWS-FLI1 peaks, respectively. Importantly, 854 (46.9%)
showed concomitant EWS-FLI1, E2F3 and E2F4 binding
(Figure 1A). Similar results were obtained using an alter-
native peak calling strategy (MACS2) as described in the
supporting material. Here, E2F4 frequently occupied ex-
actly the same binding sites in aberrant ETS/E2F regulated
promoters as E2F3 (Supplementary Figure S1) suggesting
a binding competition between the two counteracting E2F
factors. Since binding of EWS-FLI1 or TMPRSS2-ERG to
these promoters is associated with gene activation (14), we
studied the influence of EWS-FLI1 modulation on quan-
titative E2F3 and E2F4 occupation of selected target pro-
moters (E2F3, ATAD2, RAD51) by semi-quantitative and
real-time quantitative ChIP-qPCR before and at different
time points after induced EWS-FLI1 silencing in A673 ES
cells carrying doxycycline controllable EWS-FLI1 shRNA
(15).
For the E2F3 gene, three areas of EWS-FLI1/E2F3
binding were investigated at (-272/-149), (-123/62) and
(131/262) relative to the transcription start site (TSS). As
negative control, an upstream region (-1457/-1334) devoid
of ETS and E2F recognition sites was used. In the presence
of the oncogene, ChIP assays revealed strong binding of
E2F3 but weak binding of E2F4 to all three tested promoter
sites.With increasing time after the induction of EWS-FLI1
knockdown, E2F3 promoter occupancy by E2F3 decreased
while E2F4 binding increased. This replacement of E2F3 by
E2F4 on the E2F3 promoter occurred gradually over time
with a complete exchange 48h after knockdown of EWS-
FLI1 (Figure 1B and E). The binding pattern of E2F3 and
E2F4 on the ATAD2 (Figure 1C and F) and RAD51 (Fig-
ure 1D and G) promoters resembled the E2F3 promoter
occupancy with decreasing E2F3 binding and increasing
E2F4 binding after knockdown of EWS-FLI1. Negative
control regions in the three tested promoters showed signifi-
cantly less E2F3 and E2F4 binding. In addition, promoters
of three EWS-FLI1 activated genes, bound by E2F3 and
E2F4, but, according to ChIP-seq, not EWS-FLI1, were
investigated before and after knockdown of the oncogene.
While E2F3 binding decreased slightly on two of the three
promoters (MKI67 and RAD54L) upon EWS-FLI1 mod-
ulation, E2F4 was already bound to the promoters before
Figure 1. E2F3 and E2F4 binding to target promoters: (A) Venn diagram
of gene numbers associated with E2F3, E2F4 or EWS-FLI1 binding in
A673 cells and their overlaps. Binding data for EWS-FLI1 and E2F3 are
taken from (14). (B–D) ChIP-PCR and (E–G) quantitative longitudinal
ChIP-qPCR results for three EWS-FLI1 target genes before and at differ-
ent time points after induction of EWS-FLI1 silencing. Cells were either
left untreated (0) or were treated with doxycycline for 18, 24, 36 and 48h.
E2F3 (dark green) and E2F4 (light green) ChIPs were followed by PCR
amplification of genomic regions containing putative E2F binding sites.
For control, gene regions far upstream of the TSS of the corresponding
genes devoid of E2F or ETS binding sites were used. E2F3 (B and E),
ATAD2 (C and F) and RAD51 (D and G). For control, ChIP using un-
related IgG was performed. Y axis: Promoter occupancy relative to Input.
Results are means ± SD from a representative experiment performed in at
least triplicates.
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Figure 2. E2F binding is dependent on EWS-FLI1 and independent of cell
cycle. (A) E2F3 (dark green) and E2F4 (light green) promoter occupancy
was analyzed by ChIP-qPCR on three promoters (MKI67, RAD54L and
ATAD5) identified by ChIP-seq to be bound by E2F3 and E2F4, but not
EWS-FLI1, before (0) and after (48) doxycycline induced knockdown of
EWS-FLI1. (B–G) Cells were either left untreated (untreated /control), or
treated with thymidine (B, D and F) or were transfected with a p57 expres-
sion plasmid (C, E and G), and ChIP-qPCR was performed with antibod-
ies to E2F3 (dark green) and E2F4 (light green) as well as unrelated IgG
for negative control. Regions for E2F3 (B, C), ATAD2 (D,E) and RAD51
(F, G) containing putative E2F binding sites and corresponding control
regions without binding sites were amplified. Y axis: Promoter occupancy
relative to Input. Results aremeans± SD from a representative experiment
performed in triplicates.
and not further increased after knockdown of EWS-FLI1
on all three tested promoters (Figure 2A). These results sug-
gest that on EWS-FLI1 occupied promoters, depletion of
the oncogene leads to a gradual replacement of activating
E2F3 by repressive E2F4, which is not observed on E2F3
regulated promoters lacking EWS-FLI1 binding.
For several genes, regulation by E2F factors was previ-
ously demonstrated to be cell cycle dependent (11). Since
knockdown of EWS-FLI1 in ES induces cell cycle arrest
[(22) and Supplementary Figure S2A)], we tested whether
the observed E2F3/E2F4 exchange upon inducible EWS-
FLI1 knockdown might be the consequence or the cause
of cell cycle attenuation. We employed, two different estab-
lished strategies to arrest A673 cells in G1 in the presence of
EWS-FLI1, double thymidine blockade and ectopic expres-
sion of p57 (CDKN1C/KIP2) (23,24). These experimental
settings resulted in similar proportions of cells arrested in
G1 as induced by EWS-FLI1 knockdown (Supplementary
Figure S2A), but did not affect EWS-FLI1 expression (Sup-
plementary Figure S2B). Importantly, neither thymidine
blockade nor forced p57 expression reduced E2F3 bind-
ing or significantly increased E2F4 occupancy of the E2F3,
ATAD2 andRAD51 promoters (Figure 2B–F). In addition,
although knockdown of EWS-FLI1 markedly reduces pro-
moter activity of E2F3 and RAD51 genes in luciferase re-
porter assays (14), no difference in promoter activities of
these genes was observed between control and thymidine
block conditions (Supplementary Figure S2C).
Taken together these results confirm that the replacement
of E2F3 by E2F4 and the modulation of target promoter
activities upon EWS-FLI1 knockdown is not a mere con-
sequence of induced cell cycle arrest but causally related
to the presence/absence of EWS-FLI1. We therefore hy-
pothesized that in the presence of EWS-FLI1 E2F3 is tran-
scriptionally activated and recruited to EWS-FLI1/E2F3
co-regulated promoters to replace constitutively expressed
repressive E2F4.
Pocket proteins reflect binding patterns of their E2F interac-
tion partners
Pocket protein binding toE2Fs plays a critical role in cell cy-
cle regulation. E2F3 forms a complex with pRB and E2F4
with p130 (25,26). We therefore interrogated the binding
patterns of pRB and p130 to EWS-FLI1/E2F regulated
promoters by quantitative ChIP-PCR (Figure 3). Although
absolute signal intensities varied between different promot-
ers indicative of variable affinities, pRB binding to the var-
ious tested promoters was generally reduced upon knock-
down of EWS-FLI1 as was binding of its interaction part-
ner E2F3. In contrast, binding of p130 in combination with
E2F4 increased after EWS-FLI1 depletion. These findings
indicate that E2F3 and E2F4 bind to EWS-FLI1 regulated
genes as complexes with pRB and p130, respectively.
Together, our results indicate that in the presence of
EWS-FLI1, E2F target promoters are occupied by the tran-
scriptionally activating E2F3/pRB complex. In the absence
of EWS-FLI1, this complex is replaced by the repressive
E2F4/p130 complex. Since E2F4 and p130 are constitu-
tively expressed these data support a model in which EWS-
FLI1 binding leads to dissociation of E2F4/p130 from and
recruitment of E2F3/pRB to their shared target promoters
suggesting an active regulatory role of EWS-FLI1 in coop-
erative promoter activation by E2F3.
This may be best explained by a direct physical interac-
tion of the EWS-FLI1 protein with any of the E2F/pocket
protein complexes. In order to test for interaction be-
tween EWS-FLI1 and the different E2F/pocket protein
components, we performed co-immunoprecipitation exper-
iments (Co-IP) followed by immunoblot analyses. While
E2F/pocket protein complexes were readily detectable,
no experimental evidence for physical interaction between
EWS-FLI1 and E2F/pocket protein pull-down products
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Figure 3. Pocket proteins reflect binding patterns of their E2F interaction
partners: ChIP assays were performed in A673 ESFT cells. Cells were ei-
ther left untreated (0) for control, or were treated for 48h with doxycycline
to induce knockdown of EWS-FLI1. pRB (dark green) and p130 (light
green) ChIPs were followed by qPCR amplification of promoter regions
containing ETS and/or E2F sites, and, for negative control, a region up-
stream of the corresponding TSS not containing E2F or ETS binding sites
for (A) E2F3, (B) ATAD2 and (C) RAD51. For control, ChIP using unre-
lated IgG was performed. Y-axis: Promoter occupancy relative to Input.
Results are means ± SD from a representative experiment performed in at
least triplicates.
was obtainable (Supplementary Figure S3). This result may
either be explained by a lack of complex formation between
the ES oncoprotein and E2F factors. Alternatively, the co-
occurrence of E2F3 and E2F4 on the same promoter sites
in the presence of EWS-FLI1 in ChIP experiments may re-
flect heterogeneity across the cell population which would
be expected to be observed in case of a high on/off rate of
E2F transcription factor binding.
Bayesian model selection
So far our data strongly suggested functional synergy be-
tween E2F3 and EWS-FLI1 in the activation of their shared
targets via a EWS-FLI1 induced E2F4/E2F3 exchange
mechanism. In the absence of experimental evidence for a
physical complex between EWS-FLI1 and any of the E2F
complex components, we decided to take a statistical mod-
eling approach based on longitudinal quantitative measure-
ments of EWS-FLI1, E2F3, ATAD2 and RAD51 gene ex-
pression to explain the observed functional synergy. EWS-
FLI1 and E2F3 protein levels were determined by fluo-
rescent immunoblots, and RNA expression was analyzed
by qRT-PCR using primers amplifying EWS-FLI1, E2F3,
ATAD2 and RAD51 and normalized to b-actin expression.
Samples were analyzed at 0, 10, 15, 18, 21, 24, 27, 30, 33,
36, 39, 42, 45 and 48 h of doxycycline treatment.
E2F4was excluded from themodeling approach, asRNA
and protein levels are not changing upon knockdown of
EWS-FLI1 and therefore would not provide additional in-
formation. Furthermore in the statistical modeling part of
this work, we were mainly interested in the mechanism how
EWS-FLI1 and E2F3 are regulating their shared target
genes.
The data used in the statistical analysis are avail-
able in the supporting material (Supplementary Figure
S4). Furthermore, the data as well as the accompanying
MATLAB code have been made publicly available as a
git repository at https://github.com/UniversityofWarwick/
ews fli1 and e2f nar article.
Description of mechanistic models
Bayesian model selection was used in order to answer
whether EWS-FLI1 andE2F3 proteins activate their shared
target genes independently or synergistically, exemplified by
ATAD2 and validated with RAD51. First, four candidate
mechanistic models describing possible scenarios for the
regulation of ATAD2 were constructed.
Figure 4 visualizes the mechanisms behind these four
models. Model 1 assumes that the EWS-FLI1 and E2F3
proteins independently target genes including E2F3 itself.
Model 2 postulates that target gene transcription depends
on the co-binding of EWS-FLI1 and E2F3 proteins as a
complex or separately but in interdependence. Model 3 pre-
sumes EWS-FLI1 protein activates transcription of target
genes alone without a contribution of E2F3. Finally, model
4 supposes that the EWS-FLI1 protein first activates the
transcription of E2F3, and E2F3 protein subsequently acti-
vates transcription of target genes.
It is noted that finer possible adaptations in the model-
ing of regulation of E2F3 target genes may provide varia-
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Figure 4. Candidate models for the regulation of E2F target genes by
EWS-FLI1. (A) Model1: EWS-FLI1 activates E2F3, and target gene tran-
scription is regulated independently by EWS-FLI1 and E2F3. EWS-FLI1
and E2F3 independently bind on E2F targets. (B)Model2: EWS-FLI1 and
E2F3 synergistically activate transcription. (C) Model3: Target gene acti-
vation is exclusively driven by EWS-FLI1 with no contribution of E2F3.
(D) Model4: Target gene activation is driven exclusively by E2F3, and
EWS-FLI1 regulates target gene expression indirectly through induction
of E2F3.
tions of the four candidate mechanistic models. Experimen-
tal and computational limitations have been factored in at
the stage of model construction in an attempt to establish a
representative set of the broad spectrum of plausible mod-
eling configurations.
The four mechanistic models can be described by systems
of ODEs parameterized by unknown kinetic parameters.
Allmodels comprise five states corresponding to themRNA
concentrations and protein levels of EWS-FLI1, E2F3 and
the mRNA concentrations of the target gene. ATAD2 was
used as the primary model target gene. The analysis was
subsequently rerun using RAD51 as the target to provide
reinforcing evidence in favor of the selected model.
The specifics of ODE formation and ofMCMC inference
are treated in the ‘Methods’ section of the paper, while asso-
ciated technical details are exposed more elaborately in the
supporting material.
Statistical outcome
The four candidate models have been compared on the sta-
tistical basis of the inferredBayes factors, which in turn have
been computed using the log-marginals derived viaMCMC
inference, see equation (S21) in the supporting material. It
is noted that the observation matrix Y appearing in equa-
tion (S21) corresponds to the experimental data, which are
visualized in Figure S4.
Table 2 displays the Bayes factors for the four models af-
ter running the analysis twice, once using ATAD2 and once
using RAD51 as the target gene. In both cases, the order of
the Bayes factors across the fourmodels is preserved.Model
2 is the most probable one among the four candidate mod-
els irrespectively of the target gene data (ATAD2 orRAD51)
employed in the simulations. This confirms the model of a
synergistic regulation of E2F3 target genes by EWS-FLI1
Table 2. Bayes factors for the four mechanistic models using ATAD2 and
RAD51 as target genes
Model E2F3 Target Gene
ATAD2 RAD51
1 0.65% 1.46%
2 97.35% 87.83%
3 1.88% 10.58%
4 0.13% 0.12%
and E2F3. Supplementary Figures S5 and S6 in the sup-
porting material show how model 2 fits the observed data
by using multiple simulations of the ODE system with pa-
rameters sampled from the posterior distribution. The pos-
terior means for the two noise variances, vr and vp, where
0.0111 and 0.0088 for the ATAD2 target gene and 0.0149,
0.0078 for the RAD51 target gene.
DISCUSSION
A major hallmark of oncogenesis is the deregulation of
cell cycle genes in order to promote proliferation of can-
cer cells (27). In ES, EWS-FLI1 binds to and activates the
promoters of several cell cycle regulators, in particular of
E2F transcription factor genes including E2F3, and silenc-
ing of EWS-FLI1 induces cell cycle arrest. Our previous
data suggested a feed-forward loop activation of E2F3 and
of at least 50% of E2F3 target genes by combinatorial bind-
ing of EWS-FLI1 and E2F3 (14,28). However, the molec-
ular mechanism behind synergistic EWS-FLI1/E2F target
gene activation remained unknown. In this study we ana-
lyzed the co-localization and binding dynamics of EWS-
FLI1 and E2F factors to selected promoters and applied
mathematical modeling as an approach to better under-
stand the functional synergy between oncogenic ETS and
the cellular E2F dependent gene regulatory network. As the
bona fide progenitor cell type for ES remains controversial
(3,29–32) we chose to use a tightly controllable EWS-FLI1
knockdown system in ES cells as a reverse model to infer
the basis of EWS-FLI1/E2F3 synergy. We found that the
drop in target gene expression upon knockdown of EWS-
FLI1 is accompanied by loss of E2F3/pRB and gain of
E2F4/p130 occupancy at target promoters. This E2F ex-
change was not a consequence of EWS-FLI1 knockdown-
induced cell cycle arrest but exclusively related to and pre-
sumably caused by altered availability of EWS-FLI1. Since
E2F3 expression levels vary with the availability of EWS-
FLI1, one possible mechanistic explanation for the replace-
ment of E2F3/pRB by E2F4/p130 complexes on E2F tar-
get promoters upon EWS-FLI1 knockdown is competitive
binding driven by changes in relative E2F3 and E2F4 con-
centrations. In this case, the expression of EWS-FLI1/E2F
target genes is solely dependent on E2F3 binding but not
on EWS-FLI1 promoter occupation (model 4 in Figure 4).
However, our mathematical modeling approach excluded
this possibility, with a Bayes factor <0.2% (Table 2). In
fact, our promoter ChIP-PCR data for EWS-FLI1 regu-
lated E2F target genes lacking EWS-FLI1 binding demon-
strated that the mere reduction in E2F3 levels as a conse-
quence of EWS-FLI1 knockdown was not sufficient to al-
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ter E2F4 promoter occupancy which contrasts EWS-FLI1
binding promoters. Also, we excluded the possibility that
EWS-FLI1 acts as a mere hijacker of E2F target genes acti-
vating them independently of E2F3/pRBbinding and activ-
ity (models 1 and 3 of Figure 4). The fact that themodel pos-
tulating EWS-FLI1 as the only relevant activator of EWS-
FLI1/E2F target genes (model 3) was slightly more prob-
able than the model proposing co-regulation by indepen-
dent promoter binding of EWS-FLI1 and E2F3 (model 1;
Bayes factors 1.88 and 10.58 for ATAD2 and RAD51, re-
spectively, versus 0.46 and 1.65) might already indicate a
dominant role of EWS-FLI1 as a driver of E2F target gene
activation.However, the by farmost probablemodel (model
2 in Figure 4; Bayes factor 97.35 and 87.83 for ATAD2
and RAD51, respectively) predicts synergy either through
physical and/or functional interaction between EWS-FLI1
and an E2F3 complex as a necessary prerequisite for com-
binatorial promoter binding and activation. It is in accor-
dance with our previously published observations that mu-
tation of the ETS binding motif prevents E2F3 binding,
while mutation of the E2F site does not affect EWS-FLI1
occupation of their shared target promoters, and that the
frequency of co-occurrence of EWS-FLI1 and E2F3 bind-
ing in promoter regions is significantly more frequent than
expected by chance (14). These results suggest that, when
present, EWS-FLI1 not only induces but also recruits ac-
tivating E2F3/pRB complexes to promoters which, in the
absence of EWS-FLI1, are restrained by repressive and con-
stitutively expressed E2F4/p130 complexes.
In support of our model, Freedman et al. demonstrated
in a glioblastoma cell line for the Cdc6 promoter that acti-
vating and repressive E2Fs can bind to the same site, and
that the interaction with co-factors binding to DNA mo-
tifs in the vicinity determines the fate of target gene ex-
pression by selecting for activating E2F3 instead of E2F4
(33). Similarly, in prostate stromal cells, androgen recep-
tor (AR) physically interacts with E2F1 in gene activa-
tion, although this interaction was independent of andro-
gen binding and no evidence for the involvement of pocket
proteins was obtained (34). EWS-FLI1 may represent an-
other such example functionally interacting with an acti-
vating E2F factor. However, we were unable to experimen-
tally demonstrate protein interaction between EWS-FLI1
and E2F3/pRB complexes.
Several reasons may account for this deficiency. Among
them are low affinity and high turn-over binding, or depen-
dence on chromatin structure. Since the N-terminal region
of EWS-FLI1 was demonstrated to associate with HDAC1
(35), it is also possible that EWS-FLI1/E2F3 communica-
tion occurs through a transient interaction with the repres-
sive pRB/E2F3/HDAC1 complex leading to complex dis-
ruption and the release of active E2F3 eventually induc-
ing target gene expression (36). The systems biology ap-
proach applied in this study enabled us to overcome the
bottleneck in experimental evidence. Based solely on time
resolved RNA and protein expression data we were able
to clearly select an explanation model for EWS-FLI1 de-
pendent empirical target expression kinetics. More sensitive
methods are likely necessary to experimentally consolidate
this model. Bimolecular fluorescence complementation as-
says could be used to validate the interaction of EWS-FLI1
with E2F factors and/or pocket proteins. Affinity purifi-
cation coupled to mass spectrometry to detect interaction
partners would be an alternative option. However, due to
the intrinsically disordered nature of EWS-FLI1, this ap-
proach may not be successful (37). Furthermore singe cell
studies to follow the exchange would be useful to exclude
heterogeneity of the cell population.
In summary, an integrative analysis and mathematical
modeling of time resolved gene expression and ChIP data
for EWS-FLI1, E2F3, E2F4 and two target genes revealed
that EWS-FLI1 facilitates E2F3/pRB recruitment to target
genes that are otherwise restrained by repressive E2F4/p130
complexes. This study provides an excellent example for the
power of systems biology in the study of complex gene reg-
ulatory mechanisms that are otherwise difficult to assess ex-
perimentally.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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